S-4355-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Ron Wyden (D-OR)
What it does
This bill would require the Secretary of Health and Human Services to publicly release — within 30 days of enactment — all records, contracts, communications, and agreements between the federal government and drug manufacturers entered into on or after January 20, 2025, that involve most-favored-nation pricing, direct-to-consumer drug sales, tariff exemptions, U.S. investment commitments, special treatment in Medicare/Medicaid demonstration projects, Strategic National Stockpile purchasing agreements, or FDA priority review vouchers. It names 16 specific pharmaceutical companies whose agreements must be disclosed. It would also require the Congressional Budget Office and Government Accountability Office to jointly analyze the economic and budgetary effects of all disclosed agreements within 90 days, and mandate a report to five congressional committees.
Who benefits
Patients and consumers who would gain visibility into how drug pricing deals may affect their out-of-pocket costs. Medicare and Medicaid enrollees (approximately 150 million combined) whose program costs may be affected by these agreements. Uninsured individuals, who would receive a specific cost-savings breakdown under the required CBO/GAO analysis. Generic drug manufacturers and competing pharmaceutical companies who may be disadvantaged by undisclosed special treatment given to named companies. Health insurers and pharmacy benefit managers seeking to understand formulary and pricing impacts. Congressional oversight committees and independent researchers studying drug pricing. Journalists and public interest organizations monitoring executive branch negotiations.
Who is hurt
The 16 named pharmaceutical manufacturers (including Pfizer, Eli Lilly, Johnson & Johnson, and others) whose confidential negotiating terms and business strategies could be exposed to competitors and the public. The Executive Office of the President, which conducted these negotiations and may view mandatory disclosure as constraining future deal-making leverage. Drug manufacturers in future negotiations, who may receive less favorable terms if counterparties anticipate mandatory disclosure. Foreign governments whose pricing data is referenced in most-favored-nation agreements, as disclosure could affect their own negotiating positions. HHS staff who would face a tight 30-day implementation window.
Supporters argue
Supporters argue that agreements between the federal government and private drug companies that affect Medicare, Medicaid, and consumer drug prices are inherently matters of public interest and should not be shielded from congressional or public scrutiny. They contend that without disclosure, Congress cannot assess whether these deals deliver genuine savings or instead provide manufacturers with regulatory favors — such as exemptions from CMMI demonstration projects or guaranteed stockpile contracts — that offset any price reductions. They further argue that the bill's permitted-withholding provisions already protect legitimately proprietary pricing data, making the secrecy of the full agreements unjustifiable.
Opponents argue
Opponents argue that mandatory disclosure of confidential negotiating terms would undermine the executive branch's ability to strike future drug pricing agreements, as manufacturers would be less willing to offer concessions knowing the full terms will become public and available to competitors. They contend that some agreements may involve legally protected trade secrets or foreign-law confidentiality obligations that the bill's redaction provisions cannot fully accommodate, potentially exposing the government to breach-of-contract liability. They further argue that the 30-day disclosure deadline and the breadth of covered documents — including metadata, meeting notes, and directives — imposes an operationally unrealistic burden on HHS and other agencies.